All News

#OP0219 Population based matched medical record database study in PsA vs. non PsA from Israel: -> no differences in mortality -> BL predictors of death -higher risk: higher age, male sex, prior hospitalisation, prior psoriasis, comorbidties -lower: csDMARDs #EULAR2021 #RheumNow

Paul Studenic Stiddyo ( View Tweet)

@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

Making decisions session at #EULAR2021 @DanielAletaha When designing for a superiority trial you cannot conclude on non-inferiority. Trials in JAK-i show more or less similar efficacy results to #TNFi Some JAK-i might work better for specific patient #pain #EULAR2021 @RheumNow https://t.co/Bo81nwBFbZ
Paul Studenic Stiddyo ( View Tweet)
#OP0220 EuroSpA 17 European registries 17452 bionaive PsA Patients 1999-2018: BL age, disease duration, disease activity decreased 99-18 - disease activity progressively decreased on treatment - At 6M REM rates higher in recent years, 24M REM rates similar #EULAR2021 @RheumNow https://t.co/gZ4tOpRLIf
Paul Studenic Stiddyo ( View Tweet)
OP0318 What to consider when tapering DMARDs RETRO – RA pat with DAS<2.6 for >=6months randomised to 3 strategies: remain – taper to 50% - taper then STOP HR for flare 3|4.3 for TAP|STOP Remission depth, disease duration and RF/ACPA as risks to consider #EULAR2021 @RheumNow https://t.co/SR4NDKKrGN
Paul Studenic Stiddyo ( View Tweet)
#POS0660 Integrated data analyses of the DARWIN, and FINCH studies (7 in total) on #filgotinib and #statin use: > Around 10% of 4057 RA patients used statins at baseline > Muscle related AE were rare with no clear relation to filgotinib #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

#POS0930 @XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at week 12 of 473 ax-PsA using MAXIMISE trial data (#Secukinumab) -> Only nail dystrophy OR: 3 (150mg) OR: 5 (300mg) 🤔But why? #EULAR2021 @RheumNow https://t.co/srb6jGgBqe
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021 live might close but there is still on demand until the 4th of July. Interested in my poster: showing that quality of life in at-risk for #RA individuals is reduced but still differ from RA.. have a look at #POS1441 New insights in "pre-disease phase" @RheumNow https://t.co/xtyEgElYkX
Paul Studenic Stiddyo ( View Tweet)
What kind of trials would help you in making a decision which DMARD to choose if a patient is not meeting #T2T goal? #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

Norwegian Cardio-Rheuma register review of PsA incidence 32/100,000 pyrs, 28 among 🚹 & 35 among 🚺,highest in 50-59 yo pts. MTX initiated >50% PsA cases w/in 1 yr from index date, 19% used biologic DMARDs w/in 2 yrs. Abstract #POS1041 #EULAR2021 @RheumNow https://t.co/2PGVfeoFV9 https://t.co/CT9WTzcdcc

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Italian PsABio cohort study: UST ⬆️ overall persistence vs TNFi, especially in females, in monotherapy, BMI <25 or >30 kg/m2, & UST as 2nd-line tx. At 1 year, both UST & TNFi pts showed similar cDAPSA & MDA/VLDA. Abstract #POS1021 #EULAR2021 @RheumNow https://t.co/DGRXmPiTiD https://t.co/s7zMuSBEWt

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
More data from @rheum_covid presented by @mugartegil showing prognostic factors in patients with SLE & COVID-19 Factors related with poor prognosis: -Male, Age, Comorbidities -Time period (1st wave) -GC doses -Disease activity - No enough data for RTX or Beli #EULAR2021 #LUPUS https://t.co/ts8QsyR5KA
José A. Gómez Puerta DrGomezPuerta ( View Tweet)
What is the highest level reaction you have seen to COVID vaccine? @RheumNow #EULAR2021

Richard Conway RichardPAConway ( View Tweet)

Dr Pupim presents data on GM-CSF inhibitor mavrilimumab to treat non-ventilated COVID-19 with systemic hyperinflammation 65% ⬇️ ventilation/death day 29 (p=0.02) 61% ⬇️ death day 29 (p=0.07) @RheumNow #EULAR2021 Abstr#LB0001 https://t.co/VBPyv4Kbv7
Richard Conway RichardPAConway ( View Tweet)
Dr Ruperto on secukinumab in ERA and JPsA subtypes of JIA. HR 0.28; 95%CI 0.13–0.63 p<0.001 for flare to week 100. 87.2%, 83.7%, 67.4%, 38.4% and 24.4% of pts achieved JIA ACR 30/50/70/90/100 @RheumNow #EULAR2021 Abstr#LB0004 https://t.co/envFupqqV2
Richard Conway RichardPAConway ( View Tweet)
Dr Diekmann presents on rheumatic irAEs in different cancers. More common melanoma than NSCLC. SpA most common. Occurrence associated better tumour response. Good response to immunosuppression @RheumNow #EULAR2021 Abstr#POS0293 https://t.co/0tSHSbRq40
Richard Conway RichardPAConway ( View Tweet)
Dr Chatzis presents risk prediction model for MALT lymphoma in Sjogrens. Cryoglobulinaemia and ESSDAI at diagnosis only predictors. AUROC 0.78 for model @RheumNow #EULAR2021 Abstr#POS0290 https://t.co/cLmiMgnpwF
Richard Conway RichardPAConway ( View Tweet)
Quiz yourself. Which of the following is NOT a risk factor for HCQ associated conduction abnormalities? #EULAR2021 @RheumNow

k dao KDAO2011 ( View Tweet)

Deep learning for SLE #POS0351 👉use of AI to ID potential targets/dz pathways 👉gene ranked using metric expression & interactivity 👉many IFN and JAK/STAT genes ranked high 👉strong assc w/new pathways related to CD4+Tcell different'n, macs, denditric cells #EULAR2021 @rheumnow https://t.co/JF7NFeX4E7
k dao KDAO2011 ( View Tweet)
Not an expert in capillaroscopy? Not an issue! https://t.co/jHNKDtafQC: an automatic image reading system able to detect: -Normal capillaries Se 79.8% Spe 82% -Megacapillaries Se 89.4% Spe 78.8% -Hemorrhages (Se 71% She 73.9%) compared to expert #POS0256 #EULAR2021 @Rheumnow https://t.co/MR8enBO0de

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
×